Coherus BioSciences (CHRS)

• Market cap: $151M
• 1 day: -5.04%
• 5 days: -10.20%
• 1 month: -7.69%
• 3 months: 50.72%
• 6 months: -22.35%
• Year to date: -5.71%
• 1 year: -48.84%
• 5 years: -93.15%
• 10 years: -93.54%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Employees: 306

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

28% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 32

13% more call options, than puts

Call options by funds: $78K | Put options by funds: $69K

4% less funds holding

Funds holding: 134 [Q2] → 129 (-5) [Q3]

5.81% less ownership

Funds ownership: 72.66% [Q2] → 66.85% (-5.81%) [Q3]

14% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 21

45% less capital invested

Capital invested by funds: $144M [Q2] → $80M (-$64.2M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 355% upside
• Avg. target: $6.50 392% upside
• High target: $7 430% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Colleen Kusy 25% 1-year accuracy 5 / 20 met price target	355% upside $6	Outperform Maintained	5 Dec 2024
HC Wainwright & Co. Douglas Tsao 31% 1-year accuracy 54 / 173 met price target	430% upside $7	Buy Reiterated	4 Dec 2024